Key Takeaways Nektar Therapeutics (NKTR) announced that the phase IIb REZOLVE-AD study evaluating its lead pipeline candidate, rezpegaldesleukin (rezpeg), in patients with moderate-to-severe atopic dermatitis, met its primary and key secondary endpoints. The REZOLVE-AD study evaluated three doses of subcutaneous rezpeg (24 µg/kg, 18 µg/kg and 24 µg/kg) in patients with moderate-to-severe atopic dermatitis, also known as eczema. The study met its primary endpoint of mean improvement in Eczema Area and Severi ...

NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, the company’s President and CEO, along with Amy Sullivan, the company’s CFO, and Qasim Ahmad, MD, the company’s CMO, will be participating in a fireside chat at the TD Cowen 6th Annual Oncology Summit: Insights for ASCO & EHA being held virtually May 27-28, 2025. Additionally ...